CN103797006B - 用作端锚聚合酶抑制剂的4-哌啶基化合物 - Google Patents
用作端锚聚合酶抑制剂的4-哌啶基化合物 Download PDFInfo
- Publication number
- CN103797006B CN103797006B CN201280043558.7A CN201280043558A CN103797006B CN 103797006 B CN103797006 B CN 103797006B CN 201280043558 A CN201280043558 A CN 201280043558A CN 103797006 B CN103797006 B CN 103797006B
- Authority
- CN
- China
- Prior art keywords
- oxo
- piperidin
- benzoyl
- ylmethyl
- pyrimidin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 COc(cc1)ccc1C(C(CC1)CCN1C(CCN1CC#N)C1=*)=O Chemical compound COc(cc1)ccc1C(C(CC1)CCN1C(CCN1CC#N)C1=*)=O 0.000 description 2
- YICVTBRIXSMUIH-UHFFFAOYSA-N CCOC(CN(CCC1N(CC2)CCC2C(c(cc2)ccc2OC)=O)C1=O)=O Chemical compound CCOC(CN(CCC1N(CC2)CCC2C(c(cc2)ccc2OC)=O)C1=O)=O YICVTBRIXSMUIH-UHFFFAOYSA-N 0.000 description 1
- LPLAHBRCXQRJGP-UHFFFAOYSA-N CCOCCN(CCC1Br)C1=O Chemical compound CCOCCN(CCC1Br)C1=O LPLAHBRCXQRJGP-UHFFFAOYSA-N 0.000 description 1
- JSYSFJYDTYMNJV-UHFFFAOYSA-O C[NH2+]C(NC(CN(CCC1N(CC2)CCC2C(c(cc2)ccc2OC)=O)C1=O)=O)=NN=N Chemical compound C[NH2+]C(NC(CN(CCC1N(CC2)CCC2C(c(cc2)ccc2OC)=O)C1=O)=O)=NN=N JSYSFJYDTYMNJV-UHFFFAOYSA-O 0.000 description 1
- DUCZLEBAUSAZOC-NRFANRHFSA-N Cc(cc(cc1)C(C(CC2)CCN2[C@@H](CCN2Cc3nc(C=CC=CC4=O)c4[nH]3)C2=O)=O)c1OC Chemical compound Cc(cc(cc1)C(C(CC2)CCN2[C@@H](CCN2Cc3nc(C=CC=CC4=O)c4[nH]3)C2=O)=O)c1OC DUCZLEBAUSAZOC-NRFANRHFSA-N 0.000 description 1
- DDIZJESACWEABB-HXUWFJFHSA-N O=C(C(CC1)CCN1[C@H](CCN1CC(N2)=NC(CCOC3)=C3C2=O)C1=O)c(cc1)ccc1F Chemical compound O=C(C(CC1)CCN1[C@H](CCN1CC(N2)=NC(CCOC3)=C3C2=O)C1=O)c(cc1)ccc1F DDIZJESACWEABB-HXUWFJFHSA-N 0.000 description 1
- PJVMVQJOLWEKJV-GSVOUGTGSA-N O=C1NCC[C@H]1Cl Chemical compound O=C1NCC[C@H]1Cl PJVMVQJOLWEKJV-GSVOUGTGSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161507321P | 2011-07-13 | 2011-07-13 | |
| US61/507,321 | 2011-07-13 | ||
| PCT/IB2012/053613 WO2013008217A1 (en) | 2011-07-13 | 2012-07-13 | 4 - piperidinyl compounds for use as tankyrase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103797006A CN103797006A (zh) | 2014-05-14 |
| CN103797006B true CN103797006B (zh) | 2016-01-27 |
Family
ID=46604017
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201280043558.7A Expired - Fee Related CN103797006B (zh) | 2011-07-13 | 2012-07-13 | 用作端锚聚合酶抑制剂的4-哌啶基化合物 |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US9163003B2 (enExample) |
| EP (1) | EP2731940B1 (enExample) |
| JP (1) | JP5957077B2 (enExample) |
| KR (1) | KR20140051944A (enExample) |
| CN (1) | CN103797006B (enExample) |
| AP (1) | AP2014007400A0 (enExample) |
| AU (1) | AU2012282076A1 (enExample) |
| BR (1) | BR112014000792A2 (enExample) |
| CA (1) | CA2841932A1 (enExample) |
| CO (1) | CO6880065A2 (enExample) |
| CR (1) | CR20140071A (enExample) |
| DO (1) | DOP2014000012A (enExample) |
| EA (1) | EA201490272A1 (enExample) |
| ES (1) | ES2548513T3 (enExample) |
| IL (1) | IL230430A0 (enExample) |
| MA (1) | MA35342B1 (enExample) |
| MX (1) | MX2014000536A (enExample) |
| PH (1) | PH12014500126A1 (enExample) |
| TN (1) | TN2014000016A1 (enExample) |
| WO (1) | WO2013008217A1 (enExample) |
| ZA (1) | ZA201400374B (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9181266B2 (en) * | 2011-07-13 | 2015-11-10 | Novartis Ag | 2-piperidin-1-yl-acetamide compounds for use as tankyrase inhibitors |
| KR102104144B1 (ko) | 2012-03-07 | 2020-04-23 | 디 인스티튜트 오브 캔서 리서치:로얄 캔서 하스피틀 | 3-아릴-5-치환-이소퀴놀린-1-온 화합물 및 그의 치료적 용도 |
| AU2014239542A1 (en) * | 2013-03-15 | 2015-10-01 | Araxes Pharma Llc | Covalent inhibitors of KRas G12C |
| LT3030554T (lt) * | 2013-08-07 | 2018-05-10 | Merck Patent Gmbh | Piperidin-karbamido dariniai |
| WO2015036759A1 (en) | 2013-09-11 | 2015-03-19 | Institute Of Cancer Research: Royal Cancer Hospital (The) | 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use |
| WO2015135461A1 (zh) * | 2014-03-10 | 2015-09-17 | 四川海思科制药有限公司 | 取代的二氢苯并呋喃-哌啶-甲酮衍生物、其制备及用途 |
| JP6673853B2 (ja) | 2014-05-07 | 2020-03-25 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | ヘテロシクリル−ブタンアミド誘導体 |
| WO2016006975A2 (en) * | 2014-07-11 | 2016-01-14 | St Pharm Co., Ltd. | Novel imidazotriazinone or imidazopyrazinone derivatives, and use thereof |
| KR20160007347A (ko) | 2014-07-11 | 2016-01-20 | 에스티팜 주식회사 | 신규한 이미다조트리아지논 또는 이미다조피라지논 유도체, 및 이들의 용도 |
| WO2016006974A2 (en) * | 2014-07-11 | 2016-01-14 | St Pharm Co., Ltd. | Novel triazolopyrimidinone or triazolopyridinone derivatives, and use thereof |
| KR101739003B1 (ko) | 2014-07-11 | 2017-05-23 | 에스티팜 주식회사 | 신규한 트리아졸로피리미디논 또는 트리아졸로피리디논 유도체, 및 이들의 용도 |
| RU2018119935A (ru) * | 2015-11-02 | 2019-12-04 | Мерк Патент Гмбх | 1,4-дикарбонилпиперидильные производные |
| KR101777475B1 (ko) * | 2015-12-08 | 2017-09-11 | 에스티팜 주식회사 | 신규한 디히드로피라노피리미디논 유도체 및 이들의 용도 |
| AU2016378723B2 (en) | 2015-12-22 | 2021-09-30 | SHY Therapeutics LLC | Compounds for the treatment of cancer and inflammatory disease |
| US10722484B2 (en) | 2016-03-09 | 2020-07-28 | K-Gen, Inc. | Methods of cancer treatment |
| MA49458A (fr) | 2017-06-21 | 2020-04-29 | SHY Therapeutics LLC | Composés interagissant avec la superfamille ras destinés à être utilisés dans le traitement de cancers, de maladies inflammatoires, de rasopathies et de maladies fibrotiques |
| CA3121697A1 (en) | 2018-12-03 | 2020-06-11 | Merck Patent Gmbh | 4-heteroarylcarbonyl-n-(phenyl or heteroaryl) piperidine-1-carboxamides as inhibitors of tankyrases |
| EP3898609A1 (en) | 2018-12-19 | 2021-10-27 | Shy Therapeutics LLC | Compounds that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease |
| CN114787150A (zh) | 2019-08-15 | 2022-07-22 | 黑钻治疗公司 | 炔基喹唑啉化合物 |
| WO2022146614A1 (en) * | 2020-12-03 | 2022-07-07 | Washington University | Methods of treating and preventing kidney disease |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101454310A (zh) * | 2006-04-25 | 2009-06-10 | 伊莱利利公司 | 11-β-羟类固醇脱氢酶1的抑制剂 |
| US20090163545A1 (en) * | 2007-12-21 | 2009-06-25 | University Of Rochester | Method For Altering The Lifespan Of Eukaryotic Organisms |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020022636A1 (en) | 1997-09-03 | 2002-02-21 | Jia-He Li | Oxo-substituted compounds, process of making, and compositions and methods for inhibiting parp activity |
| AU2004200A (en) | 1999-01-14 | 2000-08-01 | Meiji Seika Kaisha Ltd. | Poly(adp-ribose) polymerase inhibitors consisting of pyrimidine derivatives |
| US6710058B2 (en) * | 2000-11-06 | 2004-03-23 | Bristol-Myers Squibb Pharma Company | Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors |
| DE10056312A1 (de) | 2000-11-14 | 2002-05-16 | Bayer Ag | Substituierte Amidoalkyluracile und ihre Verwendung |
| AUPR201600A0 (en) * | 2000-12-11 | 2001-01-11 | Fujisawa Pharmaceutical Co., Ltd. | Quinazolinone derivative |
| WO2002094790A1 (en) | 2001-05-23 | 2002-11-28 | Mitsubishi Pharma Corporation | Fused heterocyclic compound and medicinal use thereof |
| JP4391825B2 (ja) | 2001-12-06 | 2009-12-24 | メルク エンド カムパニー インコーポレーテッド | 有糸分裂キネシン阻害剤 |
| DE10201240A1 (de) | 2002-01-15 | 2003-07-24 | Bayer Ag | Substituierte Alkyluracile und ihre Verwendung |
| AUPS019702A0 (en) | 2002-01-29 | 2002-02-21 | Fujisawa Pharmaceutical Co., Ltd. | Condensed heterocyclic compounds |
| IL163562A0 (en) | 2002-02-19 | 2005-12-18 | Ono Pharmaceutical Co | fused pyridazine derivative compounds and drugs containing the compounds as the active ingredient |
| AUPS137402A0 (en) | 2002-03-26 | 2002-05-09 | Fujisawa Pharmaceutical Co., Ltd. | Novel tricyclic compounds |
| TWI275390B (en) | 2002-04-30 | 2007-03-11 | Wyeth Corp | Process for the preparation of 7-substituted-3- quinolinecarbonitriles |
| US7183287B2 (en) | 2003-04-03 | 2007-02-27 | Pharmacia Corporation | Substituted pyrimidinones |
| ATE440825T1 (de) | 2003-06-06 | 2009-09-15 | Vertex Pharma | Pyrimidin-derivate zur verwendung als modulatoren von atp-bindende kassette transportern |
| CL2004002050A1 (es) | 2003-08-13 | 2005-06-03 | Pharmacia Corp Sa Organizada B | Compuestos derivados de piridinonas sustituidas; su uso en el tratamiento de afecciones causadas o exacerbadas por actividad p38 map kinasa y/o tnf no regulada, tales como inflamaciones, tumores, sida y otros. |
| EP1692112A4 (en) | 2003-12-08 | 2008-09-24 | Cytokinetics Inc | COMPOUNDS, COMPOSITIONS, AND METHODS |
| GB0405101D0 (en) * | 2004-03-06 | 2004-04-07 | Astrazeneca Ab | Compounds |
| US7375102B2 (en) | 2004-06-28 | 2008-05-20 | Amgen Sf, Llc | Tetrahydroquinazolin-4(3H)-one-related and tetrahydropyrido[2,3-D]pyrimidin-4(3H)-one-related compounds, compositions and methods for their use |
| CA2569826C (en) * | 2004-06-30 | 2013-07-16 | Janssen Pharmaceutica N.V. | Substituted 2-alkyl quinazolinone derivatives as parp inhibitors |
| KR20160058972A (ko) | 2004-09-02 | 2016-05-25 | 제넨테크, 인크. | 헤지호그 신호전달에 대한 피리딜 억제제 |
| GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| WO2007002701A2 (en) | 2005-06-27 | 2007-01-04 | Amgen Inc. | Anti-inflammatory aryl nitrile compounds |
| US8466150B2 (en) | 2006-12-28 | 2013-06-18 | Abbott Laboratories | Inhibitors of poly(ADP-ribose)polymerase |
| TWI471134B (zh) | 2007-09-12 | 2015-02-01 | Genentech Inc | 肌醇磷脂３－激酶抑制劑化合物及化療劑之組合及使用方法 |
| CA2701292C (en) | 2007-10-25 | 2015-03-24 | Genentech, Inc. | Process for making thienopyrimidine compounds |
| KR20100089869A (ko) | 2007-11-05 | 2010-08-12 | 노파르티스 아게 | Ｗｎｔ 활성화의 측정 및 ｗｎｔ-관련 암의 치료를 위한 방법 및 조성물 |
| KR101179753B1 (ko) | 2007-11-06 | 2012-09-04 | 제일약품주식회사 | 신규한 트리시클릭 유도체 또는 이의 약학적으로허용가능한 염, 이의 제조방법 및 이를 포함하는 약학조성물 |
| HRP20150139T1 (hr) | 2008-03-27 | 2015-05-22 | Janssen Pharmaceutica N.V. | Tetrahidrofenanthridinoni i tetrahidrociklopentakinolinoni kao inhibitori parp i polimerizacije tubulina |
| US9181266B2 (en) * | 2011-07-13 | 2015-11-10 | Novartis Ag | 2-piperidin-1-yl-acetamide compounds for use as tankyrase inhibitors |
-
2012
- 2012-07-13 AP AP2014007400A patent/AP2014007400A0/xx unknown
- 2012-07-13 BR BR112014000792A patent/BR112014000792A2/pt not_active IP Right Cessation
- 2012-07-13 US US14/154,173 patent/US9163003B2/en not_active Ceased
- 2012-07-13 EP EP12742957.9A patent/EP2731940B1/en not_active Not-in-force
- 2012-07-13 JP JP2014519688A patent/JP5957077B2/ja not_active Expired - Fee Related
- 2012-07-13 ES ES12742957.9T patent/ES2548513T3/es active Active
- 2012-07-13 PH PH1/2014/500126A patent/PH12014500126A1/en unknown
- 2012-07-13 EA EA201490272A patent/EA201490272A1/ru unknown
- 2012-07-13 US US15/786,125 patent/USRE46942E1/en active Active
- 2012-07-13 WO PCT/IB2012/053613 patent/WO2013008217A1/en not_active Ceased
- 2012-07-13 KR KR20147003628A patent/KR20140051944A/ko not_active Withdrawn
- 2012-07-13 MX MX2014000536A patent/MX2014000536A/es not_active Application Discontinuation
- 2012-07-13 CA CA 2841932 patent/CA2841932A1/en not_active Abandoned
- 2012-07-13 AU AU2012282076A patent/AU2012282076A1/en not_active Abandoned
- 2012-07-13 CN CN201280043558.7A patent/CN103797006B/zh not_active Expired - Fee Related
-
2014
- 2014-01-13 IL IL230430A patent/IL230430A0/en unknown
- 2014-01-15 TN TNP2014000016A patent/TN2014000016A1/en unknown
- 2014-01-17 ZA ZA2014/00374A patent/ZA201400374B/en unknown
- 2014-01-22 DO DO2014000012A patent/DOP2014000012A/es unknown
- 2014-02-10 MA MA36745A patent/MA35342B1/fr unknown
- 2014-02-12 CR CR20140071A patent/CR20140071A/es unknown
- 2014-02-13 CO CO14031176A patent/CO6880065A2/es not_active Application Discontinuation
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101454310A (zh) * | 2006-04-25 | 2009-06-10 | 伊莱利利公司 | 11-β-羟类固醇脱氢酶1的抑制剂 |
| US20090163545A1 (en) * | 2007-12-21 | 2009-06-25 | University Of Rochester | Method For Altering The Lifespan Of Eukaryotic Organisms |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2012282076A1 (en) | 2014-02-27 |
| CA2841932A1 (en) | 2013-01-17 |
| TN2014000016A1 (en) | 2015-07-01 |
| BR112014000792A2 (pt) | 2017-10-31 |
| KR20140051944A (ko) | 2014-05-02 |
| CN103797006A (zh) | 2014-05-14 |
| MX2014000536A (es) | 2014-12-05 |
| AP2014007400A0 (en) | 2014-01-31 |
| IL230430A0 (en) | 2014-03-31 |
| US20150126513A1 (en) | 2015-05-07 |
| MA35342B1 (fr) | 2014-08-01 |
| JP2014522855A (ja) | 2014-09-08 |
| ZA201400374B (en) | 2014-10-29 |
| WO2013008217A1 (en) | 2013-01-17 |
| CO6880065A2 (es) | 2014-02-28 |
| ES2548513T3 (es) | 2015-10-19 |
| EA201490272A1 (ru) | 2014-05-30 |
| PH12014500126A1 (en) | 2014-02-24 |
| EP2731940B1 (en) | 2015-08-19 |
| CR20140071A (es) | 2014-10-16 |
| USRE46942E1 (en) | 2018-07-10 |
| NZ620426A (en) | 2015-08-28 |
| DOP2014000012A (es) | 2014-07-31 |
| JP5957077B2 (ja) | 2016-07-27 |
| EP2731940A1 (en) | 2014-05-21 |
| US9163003B2 (en) | 2015-10-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103797006B (zh) | 用作端锚聚合酶抑制剂的4-哌啶基化合物 | |
| US9181266B2 (en) | 2-piperidin-1-yl-acetamide compounds for use as tankyrase inhibitors | |
| CN116888120A (zh) | Prmts抑制剂 | |
| CN118388454A (zh) | Bcl6蛋白水解的调节剂和其相关使用方法 | |
| JP2021520350A (ja) | Ｂｒｍ標的化化合物および関連使用方法 | |
| WO2020200158A1 (zh) | 用于治疗癌症的氮杂芳环酰胺衍生物 | |
| US12233065B2 (en) | Inhibitors of RNA helicase DHX9 and uses thereof | |
| CN102015705A (zh) | 稠合的杂环衍生物及其用途 | |
| BR112020019111A2 (pt) | Derivados de imidazolidin-2-ona substituída como inibidores de prmt5 | |
| AU2021289169B2 (en) | Spiro compounds as melanocortin 4 receptor antagonists and uses thereof | |
| CN103814032A (zh) | 用作端锚聚合酶抑制剂的4-氧代-3,5,7,8-四氢-4H-吡喃并[4,3-d]嘧啶基化合物 | |
| CN113272297B (zh) | 作为h4拮抗剂化合物的吡唑衍生物 | |
| WO2021204626A1 (en) | Aryl and heteroaryl-carboxamide substituted heteroaryl compounds as tyk2 inhibitors | |
| CN105829294B (zh) | ROR-γ-T的与亚甲基连接的喹啉基调节剂 | |
| TW202140499A (zh) | 巨環ｒｉｐ２－激酶抑制劑 | |
| TW201111367A (en) | Hedgehog signal inhibitor | |
| KR20240099171A (ko) | 6-아자-퀴놀린 유도체 및 관련 용도 | |
| CN107848971B (zh) | 杂环化合物 | |
| WO2021020585A1 (ja) | 複素環化合物 | |
| TW202448473A (zh) | 包含ｓｏｓ１抑制劑及抗癌藥物的用於治療癌症之藥學組成物 | |
| CN118510764A (zh) | 新颖苯并咪唑吡啶衍生物 | |
| CN116836167A (zh) | 咪唑并[1,2-a]吡嗪或吡唑并[1,5-a]嘧啶衍生物及其用途 | |
| TW202432544A (zh) | 快速加速纖維肉瘤降解化合物及相關使用方法 | |
| NZ620426B2 (en) | 4-piperidinyl compounds for use as tankyrase inhibitors | |
| EA046513B1 (ru) | Замещенные производные имидазолидин-2-она в качестве ингибиторов prmt5 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20160127 Termination date: 20200713 |